TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10069912

Group type: EXPERIMENTAL
Intervention: Hypertonic saline with lidocaine (LIDO)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Hypertonic saline alone (HS)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups (LIDO and HS)
Number of subjects: 42
Study: 7562241

Group type: EXPERIMENTAL
Intervention: Cyclosporin G (CsG) at low dose (5 mg/kg/day)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Cyclosporin G (CsG) at high dose (10 mg/kg/day)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Cyclosporin G (CsG) during tapering to lower doses
Number of subjects: 107
Study: 2109330

Group type: EXPERIMENTAL
Intervention: 35% CO2 in oxygen inhalation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Compressed air (placebo control)
Number of subjects: 50
Study: 6791936

Group type: EXPERIMENTAL
Intervention: Single intravenous injection of synthetic salmon calcitonin (2-200 i.u.)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Repeated administration of synthetic salmon calcitonin (10-200 i.u. thrice weekly for up to 2 months)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Repeated administration of synthetic salmon calcitonin
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Calcium absorption (six studies) during treatment
Number of subjects: 21
Study: 31825266

Group type: EXPERIMENTAL
Intervention: Therapeutic songwriting intervention
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 132
Study: 31261260

Group type: COMPARATOR
Intervention: 5° Trendelenburg positioning
Number of subjects: 50

Group type: COMPARATOR
Intervention: 10° Trendelenburg positioning
Number of subjects: 50

Group type: COMPARATOR
Intervention: 15° Trendelenburg positioning
Number of subjects: 50
Study: 27981804

Group type: EXPERIMENTAL
Intervention: MD-Logic closed-loop system
Number of subjects: 75

Group type: COMPARATOR
Intervention: SAP therapy
Number of subjects: 75
Study: 26547349

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 µg/kg loading dose, followed by 0.3 µg·kg(‐1)·h(‐1) continuous infusion)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline infusion (control group)
Number of subjects: 60
Study: 24371021

Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride modified-release (MPH-LA) 40 mg/day
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride modified-release (MPH-LA) 60 mg/day
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride modified-release (MPH-LA) 80 mg/day
Number of subjects: 725

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride modified-release (MPH-LA) (all doses combined)
Number of subjects: 725
Study: 22954329

Group type: EXPERIMENTAL
Intervention: Surgical treatment with locking plates for two-part fractures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative treatment for two-part fractures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical treatment with Philos locking plate for multi-fragmented fractures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hemiarthroplasty with Epoca prosthesis for multi-fragmented fractures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative treatment for multi-fragmented fractures
Number of subjects: 0
Study: 19104193

Group type: EXPERIMENTAL
Intervention: Communication skills training program for nurses (2 days, 33 hours)
Number of subjects: 413
Study: 17700217

Group type: EXPERIMENTAL
Intervention: Gliclazide (G III)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Diet (G IV)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Glibenclamide (G II)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: No intervention (G I)
Number of subjects: 64
Study: 15334764

Group type: EXPERIMENTAL
Intervention: Leukocyte-reducing filter (LRF)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Standard CPB circuit with no LRF (Control)
Number of subjects: 17
Study: 11600559

Group type: EXPERIMENTAL
Intervention: Extended fasting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glucose infusion (5.8-6.5 mmol/liter)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher rates of glucose infusion (up to 8.7 mmol/liter)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All levels of glycemia
Number of subjects: 0
Study: 9641801

Group type: EXPERIMENTAL
Intervention: Brief pulse stimuli
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ultrabrief pulse stimuli
Number of subjects: 48
Study: 7947503

Group type: EXPERIMENTAL
Intervention: hCG treatment (10,000 i.u. initially, then 5000 i.u. twice weekly until miscarriage or the tenth week of pregnancy)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: hCG treatment in women with follicular phase luteinising hormone > 10 iu/l
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: hCG treatment with clomiphene for ovulation induction
Number of subjects: 191

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191

Group type: COMPARATOR
Intervention: Placebo in women with follicular phase luteinising hormone > 10 iu/l
Number of subjects: 191

Group type: COMPARATOR
Intervention: Placebo with clomiphene for ovulation induction
Number of subjects: 191
Study: 2644594

Group type: EXPERIMENTAL
Intervention: Oral antibiotics after hospital discharge
Number of subjects: 163

Group type: COMPARATOR
Intervention: No oral antibiotics after hospital discharge
Number of subjects: 163
Study: 29143569

Group type: EXPERIMENTAL
Intervention: Clenching/grinding
Number of subjects: 4204

Group type: EXPERIMENTAL
Intervention: Clicking
Number of subjects: 4204

Group type: EXPERIMENTAL
Intervention: Difficulty chewing
Number of subjects: 4204

Group type: EXPERIMENTAL
Intervention: Difficulty closing
Number of subjects: 4204

Group type: COMPARATOR
Intervention: Missing teeth association with clenching/grinding
Number of subjects: 4204

Group type: COMPARATOR
Intervention: Missing teeth association with difficulty chewing
Number of subjects: 4204

Group type: COMPARATOR
Intervention: Age and gender effects
Number of subjects: 4204
Study: 28329386

Group type: EXPERIMENTAL
Intervention: Nap group (1-hour nap opportunity at 14:00 following each sleep restriction night)
Number of subjects: 57

Group type: COMPARATOR
Intervention: No nap group
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 57
Study: 26271018

Group type: EXPERIMENTAL
Intervention: Web-Based Early Intervention
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 59
Study: 23291509

Group type: EXPERIMENTAL
Intervention: modified constraint-induced movement therapy followed by bimanual training (mCIMT-BiT)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: modified constraint-induced movement therapy (mCIMT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: conventional therapy
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: mCIMT-BiT
Number of subjects: 52
Study: 21474111

Group type: EXPERIMENTAL
Intervention: Elaborative rehearsal as a secondary task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maintenance rehearsal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition with no secondary task
Number of subjects: 0
Study: 17530428

Group type: EXPERIMENTAL
Intervention: Immediate exercise group (IEG) - 12 weeks of supervised aerobic and resistance exercise, three times per week
Number of subjects: 58

Group type: COMPARATOR
Intervention: Delayed exercise group (DEG) - completed the program during the next 12 weeks
Number of subjects: 58
Study: 16689010

Group type: EXPERIMENTAL
Intervention: Jianpi Yiqi Huoxue Decoction (JYHD)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (anti-infective and symptomatic therapy only)
Number of subjects: 58
Study: 12658059

Group type: EXPERIMENTAL
Intervention: Lisinopril (20 mg)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (30 mg)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Combination of lisinopril and nifedipine GITS
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 51
Study: 10636971

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9024279

Group type: COMPARATOR
Intervention: Normal saline (NS) bolus and NS infusion
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Naloxone (NAL) bolus (4 mg) and NAL infusion (2 mg/h)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Normal saline (NS) bolus and oCRH infusion (1 microgram/kg.h; maximum, 75 micrograms/h)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Naloxone (NAL) bolus and both NAL and oCRH infusions
Number of subjects: 11
Study: 8475703

Group type: EXPERIMENTAL
Intervention: Tono-Pen tonometry
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Tono-Pen tonometry by GPs
Number of subjects: 132
Study: 3639538

Group type: EXPERIMENTAL
Intervention: self‐paced response condition
Number of subjects: 105

Group type: COMPARATOR
Intervention: fast‐paced response condition
Number of subjects: 105

Group type: COMPARATOR
Intervention: slow‐paced response condition
Number of subjects: 105
Study: 30744053

Group type: EXPERIMENTAL
Intervention: Healthy learning. Together. (intervention group)
Number of subjects: 1144

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 1144
Study: 29037627

Group type: EXPERIMENTAL
Intervention: Continuous 3 MHz, 1.5 w/cm2 Ultrasound
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham Ultrasound
Number of subjects: 50
Study: 25977276

Group type: EXPERIMENTAL
Intervention: VASOGRADE-Green (modified Fisher scale 1 or 2 and WFNS 1 or 2)
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: VASOGRADE-Yellow (modified Fisher 3 or 4 and WFNS 1-3)
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: VASOGRADE-Red (WFNS 4 or 5, irrespective of modified Fisher grade)
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: VASOGRADE overall
Number of subjects: 746
Study: 24450889

Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy for 9 months
Number of subjects: 78744

Group type: COMPARATOR
Intervention: Control (no isoniazid preventive therapy)
Number of subjects: 78744

Group type: EXPERIMENTAL
Intervention: Intervention clusters (mass screening and treatment)
Number of subjects: 78744

Group type: COMPARATOR
Intervention: Control clusters (no intervention)
Number of subjects: 78744
Study: 22672970

Group type: EXPERIMENTAL
Intervention: 100mg/m² weekly gemcitabine with 3D conformal radiotherapy delivering 55 Gy in 20 fractions over 4 weeks (Arm B)
Number of subjects: 111

Group type: COMPARATOR
Intervention: 3D conformal radiotherapy delivering 55 Gy in 20 fractions over 4 weeks without gemcitabine (Arm A)
Number of subjects: 111
Study: 19128941

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT) trials
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Patch trials
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Trials funded by the pharmaceutical industry
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Statistically significant results
Number of subjects: 105
Study: 17496226

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy based on Fe(NO) measurements (n = 58)
Number of subjects: 118

Group type: COMPARATOR
Intervention: British Thoracic Society guidelines (control group, n = 60)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy based on Fe(NO) measurements
Number of subjects: 118
Study: 12932065

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.0625% with sufentanil 10 microg
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.1% with sufentanil 10 microg
Number of subjects: 129

Group type: COMPARATOR
Intervention: Bupivacaine 0.0625% with sufentanil 10 microg
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 129
Study: 10926311

Group type: EXPERIMENTAL
Intervention: 1200 mg ALA orally per day over 6 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 600 mg ALA intravenously over 15 minutes
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo intravenously over 15 minutes
Number of subjects: 18
Study: 9006239

Group type: EXPERIMENTAL
Intervention: Social Network (SN)
Number of subjects: 1265

Group type: EXPERIMENTAL
Intervention: Information Media (IM)
Number of subjects: 1265

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1265
Study: 1626957

Group type: EXPERIMENTAL
Intervention: Preoperative therapy-ACNU
Number of subjects: 120

Group type: COMPARATOR
Intervention: Preoperative radiotherapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ACNU combination group
Number of subjects: 120
Study: 6497641

Group type: EXPERIMENTAL
Intervention: Morphine sulfate 1 mg/kg (Group 1)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Morphine sulfate 1 mg/kg (Group 2)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Morphine sulfate 4 mg/kg (Group 3)
Number of subjects: 3
Study: 2940028

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 26242

Group type: COMPARATOR
Intervention: Control group (no BCG vaccination)
Number of subjects: 26242
Study: 29490702

Group type: EXPERIMENTAL
Intervention: Engagement with stakeholders and public to identify recruitment uncertainties
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: Prioritisation of recruitment questions through a workshop
Number of subjects: 790
Study: 27340931

Group type: EXPERIMENTAL
Intervention: Fish Oil (FO) supplementation at 4 g/day
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 24500851

Group type: EXPERIMENTAL
Intervention: LifeCath Twin (LC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Tesio catheter (TC)
Number of subjects: 80
Study: 22091734

Group type: EXPERIMENTAL
Intervention: VLS GlideScope
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: V‐Mac Storz
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: McGrath
Number of subjects: 50

Group type: COMPARATOR
Intervention: Macintosh blade
Number of subjects: 50
Study: 20392399

Group type: COMPARATOR
Intervention: Oral misoprostol (100 microg, 4 hourly, maximum of 2 doses)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (50 microg, 4 hourly, maximum of 2 doses)
Number of subjects: 100
Study: 27950588

Group type: EXPERIMENTAL
Intervention: Aggressive range of motion (ROM) exercises with postural sensory therapy
Number of subjects: 73

Group type: COMPARATOR
Intervention: Postural sensory therapy alone (PS)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Both therapy protocols
Number of subjects: 73
Study: 16831792

Group type: EXPERIMENTAL
Intervention: Group intervention
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Individual intervention
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 240
Study: 14570643

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% continuous infusion at 5 mL/h for up to 48 h after surgery
Number of subjects: 24

Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% continuous infusion
Number of subjects: 24
Study: 10761161

Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate (EES) 200 mg given orally 10 minutes after i.m. treatments
Number of subjects: 15

Group type: COMPARATOR
Intervention: Intramuscular saline (SAL, 0.5 ml), scopolamine (SCP, 0.1 mg), or promethazine (PMZ, 25 mg)
Number of subjects: 15
Study: 8883527

Group type: EXPERIMENTAL
Intervention: Iodixanol at 320 mg I/ml (IOD‐320)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Iohexol at 300 mg I/ml (IOH‐300)
Number of subjects: 49
Study: 1314242

Group type: EXPERIMENTAL
Intervention: Dexfenfluramine (dF)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 3913724

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 30932917

Group type: EXPERIMENTAL
Intervention: Pelvic floor exercise program plus vaginal electrotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pelvic floor exercise program
Number of subjects: 30
Study: 30123582

Group type: EXPERIMENTAL
Intervention: CDR+ group (induced cognitive dietary restraint)
Number of subjects: 60

Group type: COMPARATOR
Intervention: CDR- group (no induced cognitive dietary restraint)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (CDR+ and CDR-)
Number of subjects: 60
Study: 26549402

Group type: EXPERIMENTAL
Intervention: Esomeprazole (40 mg/d)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Rabeprazole (20 mg/d)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Non-PPI users
Number of subjects: 150
Study: 23900900

Group type: EXPERIMENTAL
Intervention: Plyometric training for 8 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23
Study: 22306375

Group type: EXPERIMENTAL
Intervention: Candidate Clostridium difficile toxoid vaccine (2 μg, 10 μg, or 50 μg)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 19487925

Group type: EXPERIMENTAL
Intervention: Quifenadine (2 mg kg(‐1) day(‐1); n = 54)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Amiodarone (9 mg kg(‐1) day(‐1); n = 50)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Quifenadine
Number of subjects: 104

Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 104
Study: 18668016

Group type: EXPERIMENTAL
Intervention: SNRI
Number of subjects: 0

Group type: COMPARATOR
Intervention: SSRI
Number of subjects: 0
Study: 15543591

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) alpha‐2b induction (6 MU daily for 2 weeks) followed by 6 MU thrice weekly for 46 weeks (IFN/R group)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Pegylated IFN alpha‐2b (1.5 microg/kg) weekly for 48 weeks in combination with ribavirin (600‐1,000 mg daily) (PEG/R group)
Number of subjects: 48
Study: 12784066

Group type: EXPERIMENTAL
Intervention: WEB 2086 gel (3%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9890618

Group type: EXPERIMENTAL
Intervention: Full-term neonates RBC
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Preterm infants RBC
Number of subjects: 25

Group type: COMPARATOR
Intervention: Spherocytes
Number of subjects: 25

Group type: COMPARATOR
Intervention: Elliptocytes
Number of subjects: 25

Group type: COMPARATOR
Intervention: Stomatocytes
Number of subjects: 25

Group type: COMPARATOR
Intervention: Immature RBC and knizocytes
Number of subjects: 25

Group type: COMPARATOR
Intervention: Keratocytes, akantocytes, and elliptocytes
Number of subjects: 25

Group type: COMPARATOR
Intervention: RBC volume
Number of subjects: 25
Study: 8777104

Group type: EXPERIMENTAL
Intervention: Edrophonium 1 mg kg‐1 administered 2 min after maximum block (intense block group)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Edrophonium 1 mg kg‐1 administered after 10% recovery of T1 (conventional reversal group)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Spontaneous recovery (spontaneous recovery group)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Edrophonium 1 mg kg‐1 (intense block group)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Edrophonium 1 mg kg‐1 (conventional reversal group)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Edrophonium 1 mg kg‐1 (spontaneous recovery group)
Number of subjects: 43
Study: 1802194

Group type: COMPARATOR
Intervention: Placebo with cardiovasoprotective diet
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Aspirin (180 mg daily) with fat-modified control diet
Number of subjects: 133
Study: 6185209

Group type: EXPERIMENTAL
Intervention: BLM‐MTX (bleomycin 30 mg intravenously twice weekly, methotrexate 25 mg intravenously twice weekly for 2 1/2 and two weeks, respectively)
Number of subjects: 39

Group type: COMPARATOR
Intervention: CMF (methotrexate 25 mg twice weekly for two weeks, Cytoxan 100 mg/day for two weeks, 5‐FU 500 mg twice weekly for 1 1/2 weeks)
Number of subjects: 39
Study: 28891903

Group type: EXPERIMENTAL
Intervention: Oxidized Regenerated Cellulose (ORC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Osteon II (Control)
Number of subjects: 24
Study: 26514959

Group type: EXPERIMENTAL
Intervention: Combined endo-epicardial scar homogenization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endocardial scar homogenization only (control group)
Number of subjects: 0
Study: 23670111

Group type: EXPERIMENTAL
Intervention: Mindful awareness/acceptance (MSER)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Attention-control treatment, healthy lifestyle tips (HT)
Number of subjects: 79
Study: 21107917

Group type: EXPERIMENTAL
Intervention: Experimental subjects (ES) who walked average distances of 2.7±0.6 km day(‐1) during the experimental period.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control subjects (CS) who ran average distances of 9.8±1.7 km day(‐1) during the experimental period.
Number of subjects: 20
Study: 19298338

Group type: EXPERIMENTAL
Intervention: Concomitant therapy (duration 3 to 5 days)
Number of subjects: 576

Group type: COMPARATOR
Intervention: Triple therapy (duration 5 to 10 days)
Number of subjects: 576
Study: 17854244

Group type: EXPERIMENTAL
Intervention: Citalopram (SSRI) for 4 weeks
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Reboxetine (NRI) for 4 weeks
Number of subjects: 35
Study: 15187801

Group type: EXPERIMENTAL
Intervention: Migraine
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Tension-type headache
Number of subjects: 183

Group type: COMPARATOR
Intervention: Headache-free
Number of subjects: 183
Study: 11686818

Group type: EXPERIMENTAL
Intervention: Braun Oral‐B 3D Plaque Remover D15
Number of subjects: 82

Group type: COMPARATOR
Intervention: Rowenta Dentasonic MH921S
Number of subjects: 82
Study: 9215844

Group type: EXPERIMENTAL
Intervention: Urokinase (40,000 U/h)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Urokinase with heparin (320 U/h)
Number of subjects: 42
Study: 7584270

Group type: EXPERIMENTAL
Intervention: lag6 (repeated after six intervening items)
Number of subjects: 0

Group type: COMPARATOR
Intervention: lag0 (repeated immediately)
Number of subjects: 0
Study: 3111812

Group type: EXPERIMENTAL
Intervention: Transderm-Nitro
Number of subjects: 38

Group type: COMPARATOR
Intervention: Nitro-Dur
Number of subjects: 38

Group type: COMPARATOR
Intervention: Nitrodisc
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: All three products
Number of subjects: 38
Study: 29758039

Group type: EXPERIMENTAL
Intervention: Palonosetron (0.075 mg, intravenous)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (0.9% saline)
Number of subjects: 120